Rapt Therapeutics is a clinical-stage immunology-based biopharmaceutical company. It focuses on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary drug discovery and development engine, Rapt Therapeutics aims to translate profound scientific insights into transformative medicines. The company is advancing a pipeline of wholly-owned drug candidates designed to modulate critical immune drivers of cancer and inflammation, with the goal of improving patients' lives.
The headquarters serves as the central node for the company's research and development operations, clinical trial management, corporate strategy, finance, and administrative functions.
Located within a modern biotech campus, the facility likely includes advanced laboratory spaces and an environment conducive to scientific collaboration and innovation.
Rapt Therapeutics fosters a science-driven, collaborative, and patient-focused work culture. Employees are typically engaged in dynamic, cross-functional teams dedicated to advancing novel therapeutic programs.
Its location in South San Francisco provides strategic advantages, including access to a rich talent pool, proximity to leading research institutions, and opportunities for industry collaborations.
While its primary operations and headquarters are in the United States, Rapt Therapeutics has a global reach through its clinical trial activities. The company collaborates with clinical research sites and institutions in various countries to conduct studies for its drug candidates. This international approach allows for access to diverse patient populations and medical expertise, supporting the global development pathway for its innovative therapies. Core strategic, research, and corporate functions remain centralized in the U.S.
900 Gateway Boulevard
South San Francisco
California
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Rapt Therapeutics' leadership includes:
Rapt Therapeutics has been backed by several prominent investors over the years, including:
In the past 12 months, Rapt Therapeutics has strengthened its leadership team with key appointments, including a new Chief Financial Officer and a new Chief People Officer. The company also saw the departure of its Chief Business Officer.
Discover the tools Rapt Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Rapt Therapeutics commonly uses the email format combining the first initial of an employee's first name with their full last name, followed by @rapt.com.
[first_initial][last_name]@rapt.com
Format
bwong@rapt.com
Example
75%
Success rate
GlobeNewswire • March 18, 2024
Rapt Therapeutics provided an update on its Phase 2b clinical trial of zelnecirnon (RPT193) in patients with moderate-to-severe atopic dermatitis (AD) and its Phase 2a trial in patients with eosinophilic asthma. The company decided to continue the AD trial and discontinue the asthma trial based on an interim futility analysis....more
GlobeNewswire • February 27, 2024
Rapt Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2023. The company also highlighted recent progress in its clinical programs and corporate development....more
GlobeNewswire • November 20, 2023
Rapt Therapeutics announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for tivumecirnon (RPT319), a CCR4 antagonist, for a Phase 1/2 clinical trial in patients with hematologic malignancies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Rapt Therapeutics, are just a search away.